New clause 50 debated and negatived on division (4 to 9). New clause 51 debated and withdrawn. New clause 52 negatived on division (1 to 9). New clause 56 negatived on division (1 to 9). New clause 57, discussed with new clauses 58 and 104, debated and withdrawn. New clause 66 debated and negatived on division (4 to 8). New clause 72 debated and negatived on division (2 to 9). New clause 76 negatived on division (1 to 13). New clause 77 debated and withdrawn. New clause 81, discussed with new clause 82, debated and negatived on division (4 to 9). New clause 82 negatived on division (4 to 9). New clause 83 debated and negatived on division (4 to 10). New clause 84 negatived on division (5 to 9). New clause 85, discussed with new clause 98, debated and negatived on division (5 to 9). New clause 86 debated and negatived on division (4 to 9). New clause 87, discussed with new clause 113, debated and negatived on division (5 to 9). New clause 96, discussed with new clause 97, debated and withdrawn. New clause 97 negatived on division (5 to 9). New clause 98 negatived on division (5 to 9). New clause 99 debated and negatived on division (4 to 9). New clause 101 debated and negatived on division (4 to 9). New clause 104 negatived on division (5 to 9). New clause 105, discussed with new clause 106, debated and negatived on division (4 to 9). New clause 106 negatived on division (4 to 9). New clause 108, discussed with new clause 109, debated and withdrawn. New clause 109 negatived on division (5 to 9). New clause 112, discussed with new clauses 110 and 111, debated and negatived on division (4 to 9). New schedule 1 agreed to. Clauses 68 and 69 agreed to. Clause 70, as amended, agreed to. Amendment 37 to clause 71 negatived on division (4 to 9). Amendment 38 to clause 71 negatived on division (4 to 9). Amendment 39 to clause 71 negatived on division (5 to 9). Clause 71, as amended, agreed to. Clause 72 agreed to. Bill, as amended, to be reported (Bill 131). Written evidence reported to the House.

New clause 50 debated and negatived on division (4 to 9). New clause 51 debated and withdrawn. New clause 52 negatived on division (1 to 9). New clause 56 negatived on division (1 to 9). New clause 57, discussed with new clauses 58 and 104, debated and withdrawn. New clause...

Examination of witnesses. Committee adjourned till 18 June. Written evidence reported to the House.

Examination of witnesses. Committee adjourned till 18 June. Written evidence reported to the House.

Statement on the publication of the sixth report of the Health and Social Care Committee, Palliative care (HC 1763).

Statement on the publication of the sixth report of the Health and Social Care Committee, Palliative care (HC 1763).

On behalf of the Health and Social Care Committee, it is a pleasure to present to the House our sixth report, which is on the subject of palliative care. This is the second report we are presenting to the House in as many weeks, because the Committee is in a...

On behalf of the Health and Social Care Committee, it is a pleasure to present to the House our sixth report, which is on the subject of palliative care. This is the second report we are presenting to the House in as many weeks, because the Committee is in a...

May I congratulate the hon. Lady on an excellent statement about what sounds to be a fascinating and detailed report? I was particularly impressed with the amount of time she dedicated to considering children’s palliative care. She may recall the debate in Westminster Hall earlier this month, when I mentioned...

May I congratulate the hon. Lady on an excellent statement about what sounds to be a fascinating and detailed report? I was particularly impressed with the amount of time she dedicated to considering children’s palliative care. She may recall the debate in Westminster Hall earlier this month, when I mentioned...

I commend the right hon. Gentleman for his campaigning on this issue over many years. Together for Short Lives was indeed a contributor to the two reports. Its specific recommendation on babies, children and young people’s care was that we need better specialist pan-ICB commissioning that is modelled on other...

I commend the right hon. Gentleman for his campaigning on this issue over many years. Together for Short Lives was indeed a contributor to the two reports. Its specific recommendation on babies, children and young people’s care was that we need better specialist pan-ICB commissioning that is modelled on other...

I, too, welcome the Health and Social Care Committee’s statement and thank the hon. Member for all her work in leading the Committee. We all know that we have an ageing population. It is an issue that is going to increase, and we know that the pressures on our palliative...

I, too, welcome the Health and Social Care Committee’s statement and thank the hon. Member for all her work in leading the Committee. We all know that we have an ageing population. It is an issue that is going to increase, and we know that the pressures on our palliative...

If the hon. Gentleman reads the introduction, he will see that we put the report in the context of the discussions on the assisted dying Bill. Like this House, the Committee has a range of views on the issue—for and against, and in between—but the point we make is that...

If the hon. Gentleman reads the introduction, he will see that we put the report in the context of the discussions on the assisted dying Bill. Like this House, the Committee has a range of views on the issue—for and against, and in between—but the point we make is that...

Does the Minister think it is ethical and right to administer drugs that have not been cleared through a normal process and to expedite their use? Surely we have to wait until the drugs have been properly tested.

Does the Minister think it is ethical and right to administer drugs that have not been cleared through a normal process and to expedite their use? Surely we have to wait until the drugs have been properly tested.

I do not think it would be appropriate to comment on that level of detail at this point.

I do not think it would be appropriate to comment on that level of detail at this point.

Oh!

Oh!

I hope that noble Lords can listen to what I have to say. The clinical trial processes for approved substances are, of course, an essential part as we move forward.

Amendment 703, also tabled by the noble Baroness, Lady Grey-Thompson, would not be workable in its current form. It would require...

I hope that noble Lords can listen to what I have to say. The clinical trial processes for approved substances are, of course, an essential part as we move forward.

Amendment 703, also tabled by the noble Baroness, Lady Grey-Thompson, would not be workable in its current form. It would require...

May I just clarify? I think that response was in response to my amendments to Clause 37 for the manufacture of these products. However, Amendment 552B is in respect of the limited number of designated pharmacies which were distributing these drugs. In Amendment 552, the noble Baroness, Lady Finlay, referred...

May I just clarify? I think that response was in response to my amendments to Clause 37 for the manufacture of these products. However, Amendment 552B is in respect of the limited number of designated pharmacies which were distributing these drugs. In Amendment 552, the noble Baroness, Lady Finlay, referred...

Apologies; I thank the noble Baroness for her clarification on that point. I was mid-sentence, so forgive me if I repeat myself. Limiting the number of manufacturers based on prior prescriptions is operationally impractical and could risk supply shortages.

I turn to Amendment 713A from the noble Baroness, Lady Hollins. This...

Apologies; I thank the noble Baroness for her clarification on that point. I was mid-sentence, so forgive me if I repeat myself. Limiting the number of manufacturers based on prior prescriptions is operationally impractical and could risk supply shortages.

I turn to Amendment 713A from the noble Baroness, Lady Hollins. This...

I just want to ask the Minister about her response to the noble Baroness, Lady Lawlor. She was, I think, saying to the Committee that limiting the places at which you can get the lethal drugs that will be required for death would inhibit the process. I say to her...

I just want to ask the Minister about her response to the noble Baroness, Lady Lawlor. She was, I think, saying to the Committee that limiting the places at which you can get the lethal drugs that will be required for death would inhibit the process. I say to her...

I would be happy to write to the noble Baronesses with clarification on that point; I thank them for their interventions.

As I was saying, Amendment 713A appears to introduce a parallel approvals regime, but it does not specify how that should relate to the Secretary of State’s separate power under...

I would be happy to write to the noble Baronesses with clarification on that point; I thank them for their interventions.

As I was saying, Amendment 713A appears to introduce a parallel approvals regime, but it does not specify how that should relate to the Secretary of State’s separate power under...

My Lords, I am grateful to the noble Lords who have participated in this debate. I will divide my responses thematically under four headings.

I turn first to the new scheme proposed by noble Baroness, Lady Finlay of Llandaff, in relation to how one deals with safeguarding here. The scheme would...

My Lords, I am grateful to the noble Lords who have participated in this debate. I will divide my responses thematically under four headings.

I turn first to the new scheme proposed by noble Baroness, Lady Finlay of Llandaff, in relation to how one deals with safeguarding here. The scheme would...